临床试验设计的历史进展与扩大代表性作为创新新前沿
本文回顾了疫苗与治疗评估单位(VTEU)自1962年成立以来在临床试验设计方面的创新,包括从概念验证到上市后研究、野生型挑战试验以及COVID-19期间的招聘策略。文章指出,尽管技术创新持续推动试验发展,但大流行凸显了试验中代表性不足的问题,强调社区参与和扩大人群代表性是未来临床试验创新的关键方向。
要点
- VTEU长期推动疫苗与治疗药物临床试验方法创新,覆盖从早期到实效研究。
- 野生型挑战试验已用于流感、志贺菌病、霍乱、ETEC、EPEC和疟疾疫苗初步评估。
- COVID-19大流行凸显临床试验中代表性不足,需加强社区参与和人群多样性。
核心结论
- 临床试验创新需兼顾前沿技术与社区参与,扩大代表性是未来关键挑战。
研究设计与样本
- 本文为叙述性综述,总结VTEU自1962年以来临床试验设计的创新实践。
主要发现
- VTEU开展的试验涵盖首次人体1期至建立疗效和许可决策的后期试验。
- VTEU开展了COVID-19和轮状病毒混合匹配试验以指导标准治疗。
- VTEU开发了针对流感、志贺菌病、霍乱、产肠毒素大肠埃希菌、肠致病性大肠埃希菌和疟疾的野生型挑战研究。
- COVID-19大流行期间出现了新的招聘策略并提高了疫苗临床试验的可及性。
- 大流行也凸显了临床试验中代表性改善的需求和社区参与的重要性。
临床怎么用
- 临床医生应关注临床试验中人群代表性的提升,促进社区参与以增强疫苗与治疗药物的接受度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since its establishment in 1962, the Vaccine and Treatment Evaluation Units (VTEUs) have employed cutting-edge technologies to develop novel vaccines and therapeutics to mitigate emerging public health threats in the United States and globally. Clinical trial innovation has been the hallmark of these efforts as novel approaches to testing countermeasures are investigated in pace with advances in technology and evolving public health needs. The spectrum of trials conducted by the VTEUs ranges from proof-of-concept or first-in-human phase 1 to late-phase trials that establish efficacy and inform licensure decisions or "real world" vaccine usage such as with the coronavirus disease 2019 (COVID-19) and rotavirus mix-and-match trials aimed to inform standard of care. The VTEUs have also been instrumental in developing experimental wild-type challenge studies to preliminarily assess vaccine immunogenicity against influenza, shigellosis, cholera, enterotoxigenic Escherichia coli, enteropathogenic E. coli, and malaria to help select promising vaccine candidates for further development. During the COVID-19 pandemic, novel strategies for recruitment and improved accessibility of vaccine clinical trials emerged. However, the pandemic also highlighted the need for improved representation in clinical trials and underscored the importance of community engagement. As we consider what challenges to address in the upcoming years, engagement of the population in clinical trials is critical to establishing safety and efficacy and community acceptance of vaccines and therapeutics. It is imperative to develop skills that engender community advocacy while staying on the cutting edge of science, henceforth serving as the guideposts for new frontiers in clinical trial innovation.
引用
- Jano K, Babu TM, Kottkamp AC, et al. Historical Advances in Clinical Trial Design and Expanding Representation as the New Frontier for Innovation. Clin Infect Dis. 2025. PMID: 41071742. doi:10.1093/cid/ciaf377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。